LSTA - Lisata Therapeutics

-

$undefined

N/A

(N/A)

Lisata Therapeutics NASDAQ:LSTA Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).

Location: 110 Allen Rd, New Jersey, 07920-4500, US | Website: www.caladrius.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-15.08M

Cash

38.26M

Avg Qtr Burn

-4.991M

Short % of Float

0.25%

Insider Ownership

19.13%

Institutional Own.

9.07%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LSTA12 (HONEDRA®) Details
Critical limb ischemia

Phase 3

Update

Certepetide (LSTA1) Details
Pancreatic cancer, Cancer

Susp. Mover™

Phase 2b

Data readout

LSTA1 + temozolomide Details
Cancer, Glioblastoma, Glioma

Phase 2a

Data readout

LSTA1 + Standard of care Details
Cancer, Solid tumor/s, Cholangiocarcinoma

Phase 2a

Data readout

LSTA1 + nivolumab/FOLFIRINOX, Details
Cancer, Gastroesophageal adenocarcinomas

Phase 1/2

Data readout

LSTA1 + FOLFIRINOX (neoadjuvant) + panitumumab Details
Pancreatic cancer, Cancer, Colorectal cancer

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Initiation

Failed

Discontinued

LSTA201 (CLBS201) Details
Chronic kidney disease

Failed

Discontinued

XOWNA (CLBS16) Details
Coronary Microvascular Dysfunction

Failed

Discontinued